PR Newswire
JAN 123's in vitro study on low dose naltrexone vies for the Society's "Best Research Abstract of the Year"
LAS VEGAS , Feb. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present data on two of its investigational pharmaceutical compounds at the American Society of Interventional Pain Physicians (ASIPP) annual meeting in Washington DC in March, 2023.
Dr. Amol Soin , Chief Medical Officer of JanOne, will present results from the Phase IIa trial of JAN 101, which treats patients with painful diabetic peripheral neuropathy. He will also report data from in vitro studies of JAN 123, the low-dose naltrexone that treats complex regional pain syndrome and is being readied for late-stage clinical trials to facilitate FDA approval.
Both drugs have drawn attention for their innovative targeting of the causes of pain as a strategic option for physicians seeking to avoid exposing patients to addictive opioids.
JanOne's research project titled "In Vitro Study of Development of a Biphasic Low Dose Naltrexone (2mg) To Treat Complex Regional Pain Syndrome" was chosen as a finalist for "Best Research Abstract" of the year. The winner will be announced at the ASIPP annual meeting.
"The American Society of Interventional Pain Physicians is one of the largest and most respected societies in the specialty of pain management," said Dr. Soin. "To have our work selected as a finalist at their annual meeting is a tremendous honor, and validates the great work done by our team."
Dr. Soin said he was looking forward to presenting data on the JAN 123 study on the main stage before colleagues from world-renowned institutions, physicians from large-group practices, and community physicians.
ASIPP has over 4,500 physician members. In addition to the national society, ASIPP has 48 state component societies and a large outreach to the pain management physician community.
Soin's enthusiasm was echoed by his colleague, Dr. Tony Giordano , JanOne's Chief Scientific Officer. "We are excited to present our research at ASIPP. As for having a candidate for best research abstract, we're especially honored given the peer review and strong competition. Being nominated is implied recognition of JAN 123's tremendous potential to relieve pain without the risk of having to deploy opioids."
Tony Isaac , JanOne's CEO, put the upcoming annual meeting in perspective: "While we are excited to present our work on ASIPP's national stage, we are equally motivated to bring these new therapies to those suffering from debilitating, chronic and painful diseases, such as complex regional pain syndrome and peripheral artery disease. The dedicated researchers at JanOne want to make a positive impact and ultimately improve people's quality of life."
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the statements that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of further clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope" "should", "would", "may", "potential" and other similar expressions. Such statements reflect JanOne's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by JanOne, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause JanOne's actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC").
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in JanOne's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. JanOne cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
About JanOne Inc.
JanOne is a unique Nasdaq-listed company offering innovative, actionable solutions that it believes can help create an end to the opioid crisis. JanOne is dedicated to funding resources toward innovation, technology and education to find a key resolution the national opioid epidemic, which is one of the deadliest and widespread in the country's history. The company continues to operate its legacy business – ARCA Recycling – under its current brand name. JanOne's subsidiary, ARCA Recycling, recycles household appliances by providing turnkey recycling and replacement services for utilities and other sponsors of energy efficiency programs.
Please visit www.janone.com for additional information.
Media Contact:
ir@janone.com
SOURCE JanOne Inc.